Abstract

Exhausted CD8 T (Tex) cells are a distinct cell lineage that arise during chronic infections and cancers in animal models and humans. Tex cells are characterized by progressive loss of effector functions, high and sustained inhibitory receptor expression, metabolic dysregulation, poor memory recall and homeostatic self-renewal, and distinct transcriptional and epigenetic programs. The ability to reinvigorate Tex cells through inhibitory receptor blockade, such as αPD-1, highlights the therapeutic potential of targeting this population. Emerging insights into the mechanisms of exhaustion are informing immunotherapies for cancer and chronic infections. However, like other immune cells, Tex cells are heterogeneous and include progenitor and terminal subsets with unique characteristics and responses to checkpoint blockade. Here, we review our current understanding of Tex cell biology, including the developmental paths, transcriptional and epigenetic features, and cell intrinsic and extrinsic factors contributing to exhaustion and how this knowledge may inform therapeutic targeting of Tex cells in chronic infections, autoimmunity, and cancer.

Keywords

BiologyImmunologyEpigeneticsImmune checkpointImmune systemAutoimmunityCD8PopulationCancerCytotoxic T cellEffectorT cellChronic infectionBlockadeCancer researchImmunotherapyReceptorGeneticsMedicine

MeSH Terms

AnimalsCellular SenescenceChronic DiseaseClonal AnergyCostimulatory and Inhibitory T-Cell ReceptorsEpigenesisGeneticHumansImmunotherapyNeoplasmsProgrammed Cell Death 1 ReceptorT-LymphocytesVirus Diseases

Affiliated Institutions

Related Publications

Publication Info

Year
2019
Type
review
Volume
37
Issue
1
Pages
457-495
Citations
1807
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1807
OpenAlex
71
Influential
1611
CrossRef

Cite This

Laura M. McLane, Mohamed S. Abdel-Hakeem, E. John Wherry (2019). CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annual Review of Immunology , 37 (1) , 457-495. https://doi.org/10.1146/annurev-immunol-041015-055318

Identifiers

DOI
10.1146/annurev-immunol-041015-055318
PMID
30676822

Data Quality

Data completeness: 86%